• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5007323)   Today's Articles (1104)
For: Bleumer I, Oosterwijk E, De Mulder P, Mulders PFA. Immunotherapy for renal cell carcinoma. Eur Urol 2003;44:65-75. [PMID: 12814677 DOI: 10.1016/s0302-2838(03)00191-x] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Number Cited by Other Article(s)
1
Wang H, Chen Y, Yang Y, Song R, Gu S, Cao X, Zhang L, Yang Y, Hou T, Qi X, Yang Y, Wang Y, Bai T, Feng D, Yang X, He J. MAGI3 enhances sensitivity to sunitinib in renal cell carcinoma by suppressing the MAS/ERK axis and serves as a prognostic marker. Cell Death Dis 2025;16:102. [PMID: 39956807 PMCID: PMC11830799 DOI: 10.1038/s41419-025-07427-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2024] [Revised: 01/04/2025] [Accepted: 02/04/2025] [Indexed: 02/18/2025]
2
Peired AJ, Campi R, Angelotti ML, Antonelli G, Conte C, Lazzeri E, Becherucci F, Calistri L, Serni S, Romagnani P. Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence. Cancers (Basel) 2021;13:cancers13184588. [PMID: 34572815 PMCID: PMC8466874 DOI: 10.3390/cancers13184588] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Revised: 09/07/2021] [Accepted: 09/08/2021] [Indexed: 12/11/2022]  Open
3
Nizioł J, Bonifay V, Ossoliński K, Ossoliński T, Ossolińska A, Sunner J, Beech I, Arendowski A, Ruman T. Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA. Anal Bioanal Chem 2018;410:3859-3869. [PMID: 29658093 PMCID: PMC5956006 DOI: 10.1007/s00216-018-1059-x] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 03/01/2018] [Accepted: 04/03/2018] [Indexed: 12/14/2022]
4
Ren Y, Zhao S, Chen H, Fu YM, Zhao B. Association between the expression of inhibitor of growth family member 4 and the progression of clear cell renal carcinoma. Oncol Lett 2017;14:2453-2457. [PMID: 28781682 DOI: 10.3892/ol.2017.6450] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Accepted: 04/21/2017] [Indexed: 12/23/2022]  Open
5
Wang Z, Liu N, Gan W, Li X, Zhang G, Li D, Guo H. Postoperative recurrence of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion. J Int Med Res 2017;45:1287-1296. [PMID: 28587544 PMCID: PMC5625541 DOI: 10.1177/0300060517711358] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]  Open
6
Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma. Sci Rep 2016;6:28932. [PMID: 27357243 PMCID: PMC4928052 DOI: 10.1038/srep28932] [Citation(s) in RCA: 111] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Accepted: 06/13/2016] [Indexed: 12/16/2022]  Open
7
Köpke T, Bierer S, Wülfing C, Tiemann A, Hertle L, Herrmann E. Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents. Expert Rev Anticancer Ther 2014;9:763-71. [DOI: 10.1586/era.09.37] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
8
Dornbusch J, Zacharis A, Meinhardt M, Erdmann K, Wolff I, Froehner M, Wirth MP, Zastrow S, Fuessel S. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One 2013;8:e76386. [PMID: 24086736 PMCID: PMC3785463 DOI: 10.1371/journal.pone.0076386] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Accepted: 08/30/2013] [Indexed: 01/03/2023]  Open
9
Bex A, Kerst J, Mallo H, Van Tinteren H, Horenblas S, De Gast GC. Extended Continuous Oral Temozolomide in Patients with Progressive Metastatic Renal Cell Carcinoma Not Responding to Interferon Alpha 2b. J Chemother 2013;17:674-8. [PMID: 16433200 DOI: 10.1179/joc.2005.17.6.674] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
10
Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs 2013;24:535-54. [DOI: 10.1097/cad.0b013e3283609ec1] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
11
Miyata Y, Kanda S, Sakai H, Greer PA. Feline sarcoma-related protein expression correlates with malignant aggressiveness and poor prognosis in renal cell carcinoma. Cancer Sci 2013;104:681-6. [PMID: 23445469 DOI: 10.1111/cas.12140] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2012] [Revised: 02/16/2013] [Accepted: 02/20/2013] [Indexed: 12/27/2022]  Open
12
Peungjesada S, Chuang HH, Prasad SR, Choi H, Loyer EM, Bronstein Y. Evaluation of cancer treatment in the abdomen: Trends and advances. World J Radiol 2013;5:126-42. [PMID: 23671749 PMCID: PMC3650203 DOI: 10.4329/wjr.v5.i3.126] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2012] [Revised: 01/24/2013] [Accepted: 01/31/2013] [Indexed: 02/06/2023]  Open
13
Multifaceted Kinetics of Immuno-Evasion from Tumor Dormancy. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2013;734:111-43. [DOI: 10.1007/978-1-4614-1445-2_7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
14
Staehler M, Haseke N, Roosen A, Stadler T, Bader M, Siebels M, Karl A, Stief CG. Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res 2012;15:287-91. [PMID: 20696639 PMCID: PMC3351952 DOI: 10.1186/2047-783x-15-7-287] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]  Open
15
Buti S, Bersanelli M, Donini M, Ardizzoni A. Systemic adjuvant therapies in renal cell carcinoma. Oncol Rev 2012;6:e18. [PMID: 25992216 PMCID: PMC4419621 DOI: 10.4081/oncol.2012.e18] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2012] [Revised: 07/03/2012] [Accepted: 07/05/2012] [Indexed: 12/11/2022]  Open
16
Tate DJ, Patterson JR, Velasco-Gonzalez C, Carroll EN, Trinh J, Edwards D, Aiyar A, Finkel-Jimenez B, Zea AH. Interferon-gamma-induced nitric oxide inhibits the proliferation of murine renal cell carcinoma cells. Int J Biol Sci 2012;8:1109-20. [PMID: 22991499 PMCID: PMC3445049 DOI: 10.7150/ijbs.4694] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2012] [Accepted: 08/26/2012] [Indexed: 12/23/2022]  Open
17
Amato RJ, Stephenson J, Hotte S, Nemunaitis J, Bélanger K, Reid G, Martell RE. MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma. Cancer Invest 2012;30:415-21. [PMID: 22571342 DOI: 10.3109/07357907.2012.675381] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
18
Gao H, Dong B, Jia J, Zhu H, Diao C, Yan Z, Huang Y, Li X. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases. J Cancer Res Clin Oncol 2012;138:753-61. [PMID: 22258851 DOI: 10.1007/s00432-011-1134-6] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2011] [Accepted: 12/20/2011] [Indexed: 10/14/2022]
19
Caravagna G, Barbuti R, d'Onofrio A. Fine-tuning anti-tumor immunotherapies via stochastic simulations. BMC Bioinformatics 2012;13 Suppl 4:S8. [PMID: 22536975 PMCID: PMC3303725 DOI: 10.1186/1471-2105-13-s4-s8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]  Open
20
van de Schans SAM, Aben KKH, Mulders PFA, Haanen JBAG, van Herpen C, Verhoeven RHA, Karim-Kos HE, Oosterwijk E, Kiemeney LALM. Modest improvement in 20 years of kidney cancer care in the Netherlands. Eur J Cancer 2012;48:1822-30. [PMID: 22365640 DOI: 10.1016/j.ejca.2012.01.033] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2011] [Revised: 01/27/2012] [Accepted: 01/27/2012] [Indexed: 01/20/2023]
21
Rajandram R, Bennett N, Morais C, Johnson D, Gobe G. Renal cell carcinoma: Resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins. Med Hypotheses 2012;78:330-6. [DOI: 10.1016/j.mehy.2011.11.014] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2011] [Revised: 10/17/2011] [Accepted: 11/13/2011] [Indexed: 12/25/2022]
22
Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, Rathmell WK. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol 2011;61:258-68. [PMID: 22030119 DOI: 10.1016/j.eururo.2011.10.007] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2011] [Accepted: 10/06/2011] [Indexed: 12/26/2022]
23
Wright I, Kapoor A. Current systemic management of metastatic renal cell carcinoma – first line and second line therapy. Curr Opin Support Palliat Care 2011;5:211-21. [DOI: 10.1097/spc.0b013e3283490418] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
24
Santos CI, Costa-Pereira AP. Signal transducers and activators of transcription-from cytokine signalling to cancer biology. Biochim Biophys Acta Rev Cancer 2011;1816:38-49. [PMID: 21447371 DOI: 10.1016/j.bbcan.2011.03.003] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2011] [Revised: 03/17/2011] [Accepted: 03/22/2011] [Indexed: 10/18/2022]
25
Li JW, Gong JY, Li K, Liu Y, Ye QP, Liu X, Su ZX. Construction of a fusion expression plasmid containing the G250 gene and human granulocyte-macrophage colony stimulating factor and its significance in renal cell carcinoma. Oncol Lett 2010;2:343-347. [PMID: 22866087 DOI: 10.3892/ol.2010.230] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2010] [Accepted: 12/22/2010] [Indexed: 11/06/2022]  Open
26
Tatokoro M, Fujii Y, Kawakami S, Saito K, Koga F, Matsuoka Y, Iimura Y, Masuda H, Kihara K. Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci 2010;102:137-43. [PMID: 20973869 DOI: 10.1111/j.1349-7006.2010.01756.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]  Open
27
Caravagna G, d’Onofrio A, Milazzo P, Barbuti R. Tumour suppression by immune system through stochastic oscillations. J Theor Biol 2010;265:336-45. [DOI: 10.1016/j.jtbi.2010.05.013] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2009] [Revised: 05/05/2010] [Accepted: 05/08/2010] [Indexed: 10/19/2022]
28
Hashmi MH, Van Veldhuizen PJ. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther 2010;10:807-17. [PMID: 20384523 DOI: 10.1517/14712598.2010.480971] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
29
Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, Beck J, Hofmann R, Kindler M, Kloepfer P, Stief C. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2010;29:121-6. [PMID: 20512580 DOI: 10.1007/s00345-010-0570-2] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2010] [Accepted: 05/18/2010] [Indexed: 11/24/2022]  Open
30
Xu C, Lo A, Yammanuru A, Tallarico ASC, Brady K, Murakami A, Barteneva N, Zhu Q, Marasco WA. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One 2010;5:e9625. [PMID: 20224781 PMCID: PMC2835754 DOI: 10.1371/journal.pone.0009625] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2009] [Accepted: 02/05/2010] [Indexed: 11/18/2022]  Open
31
Delay-induced oscillatory dynamics of tumour–immune system interaction. ACTA ACUST UNITED AC 2010. [DOI: 10.1016/j.mcm.2009.11.005] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
32
Herrmann E, Bierer S, Wülfing C. Update on systemic therapies of metastatic renal cell carcinoma. World J Urol 2010;28:303-9. [PMID: 20180125 DOI: 10.1007/s00345-010-0519-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2009] [Accepted: 02/08/2010] [Indexed: 11/26/2022]  Open
33
Sáenz-López P, Gouttefangeas C, Hennenlotter J, Concha A, Maleno I, Ruiz-Cabello F, Cózar JM, Tallada M, Stenzl A, Rammensee HG, Garrido F, Cabrera T. Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. ACTA ACUST UNITED AC 2010;75:110-8. [DOI: 10.1111/j.1399-0039.2009.01409.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
34
Romero-Weaver AL, Wang HW, Steen HC, Scarzello AJ, Hall VL, Sheikh F, Donnelly RP, Gamero AM. Resistance to IFN-alpha-induced apoptosis is linked to a loss of STAT2. Mol Cancer Res 2010;8:80-92. [PMID: 20068068 DOI: 10.1158/1541-7786.mcr-08-0344] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
35
Rajandram R, Pat BK, Li J, Johnson DW, Gobe GC. Expression of apoptotic tumour necrosis factor receptor-associated factor, caspase recruitment domain and cell death-inducing DFF-45 effector genes in therapy-treated renal cell carcinoma. Nephrology (Carlton) 2009;14:205-12. [PMID: 19076291 DOI: 10.1111/j.1440-1797.2008.01027.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
36
Amato RJ, Jac J, Hernandez-McClain J. Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results. Clin Genitourin Cancer 2008;6:73-8. [PMID: 18824428 DOI: 10.3816/cgc.2008.n.011] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
37
Qin W, Tian F, Wang F, Song B, Wang H, Zhang Q, Jovanovic B, Liang L, Guo Y, Smith N, Lee C. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive cytolytic T cells for treatment of established mouse Renca tumors. Urology 2008;72:943-7. [PMID: 18723212 DOI: 10.1016/j.urology.2008.04.017] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2008] [Revised: 02/22/2008] [Accepted: 04/09/2008] [Indexed: 11/18/2022]
38
Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. J Immunother 2008;31:254-62. [PMID: 18317362 DOI: 10.1097/cji.0b013e318167b023] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
39
Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K. Prognostic Impact of Postoperative C-Reactive Protein Level in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy. J Urol 2008;180:515-9. [DOI: 10.1016/j.juro.2008.04.025] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2007] [Indexed: 12/01/2022]
40
Gao H, Dong B, Liu X, Xuan H, Huang Y, Lin D. Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal Chim Acta 2008;624:269-77. [PMID: 18706333 DOI: 10.1016/j.aca.2008.06.051] [Citation(s) in RCA: 109] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2008] [Revised: 06/21/2008] [Accepted: 06/26/2008] [Indexed: 01/23/2023]
41
Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, Gamero AM. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 2008;7:1109-15. [PMID: 18698163 PMCID: PMC2435218 DOI: 10.4161/cbt.7.7.6192] [Citation(s) in RCA: 133] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]  Open
42
Pacheco AV, Rasila K, Lee SJ, Rabinowitz I, Elias L, Lee FC, Verschraegen CF. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols. Urol Oncol 2008;26:610-5. [PMID: 18367103 DOI: 10.1016/j.urolonc.2007.09.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2007] [Revised: 08/30/2007] [Accepted: 09/18/2007] [Indexed: 10/22/2022]
43
d’Onofrio A. Metamodeling tumor–immune system interaction, tumor evasion and immunotherapy. ACTA ACUST UNITED AC 2008. [DOI: 10.1016/j.mcm.2007.02.032] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
44
Guida M, Casamassima A, Monticelli G, Quaranta M, Colucci G. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. J Transl Med 2007;5:51. [PMID: 17953739 PMCID: PMC2169206 DOI: 10.1186/1479-5876-5-51] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2007] [Accepted: 10/22/2007] [Indexed: 01/29/2023]  Open
45
Thelen A, Jonas S, Benckert C, Lopez-Hänninen E, Rudolph B, Neumann U, Neuhaus P. Liver resection for metastases from renal cell carcinoma. World J Surg 2007;31:802-7. [PMID: 17354021 DOI: 10.1007/s00268-007-0685-9] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
46
Matsumoto A, Haraguchi K, Takahashi T, Azuma T, Kanda Y, Tomita K, Kurokawa M, Ogawa S, Takahashi K, Chiba S, Kitamura T. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells. Int J Urol 2007;14:277-83. [PMID: 17470153 DOI: 10.1111/j.1442-2042.2006.01723.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
47
Scarzello AJ, Romero-Weaver AL, Maher SG, Veenstra TD, Zhou M, Qin A, Donnelly RP, Sheikh F, Gamero AM. A Mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis. Mol Biol Cell 2007;18:2455-62. [PMID: 17442890 PMCID: PMC1924825 DOI: 10.1091/mbc.e06-09-0843] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2006] [Revised: 04/04/2007] [Accepted: 04/11/2007] [Indexed: 01/14/2023]  Open
48
Kudo-Saito C, Wansley EK, Gruys ME, Wiltrout R, Schlom J, Hodge JW. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2. Clin Cancer Res 2007;13:1936-46. [PMID: 17363550 DOI: 10.1158/1078-0432.ccr-06-2398] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
49
Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007;13:1801-9. [PMID: 17363536 DOI: 10.1158/1078-0432.ccr-06-1432] [Citation(s) in RCA: 121] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
50
Ranieri E, Gigante M, Storkus WJ, Gesualdo L. Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer. Clin Exp Immunol 2007;147:395-400. [PMID: 17302887 PMCID: PMC1810504 DOI: 10.1111/j.1365-2249.2006.03305.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]  Open
PrevPage 1 of 2 12Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA